logo
Share SHARE
FONT-SIZE Plus   Neg

SAP AG Q1 Prelim. Revenue Up; Backs 2012 Forecast - Quick Facts

SAP AG (SAP) reported a 11% improvement in its first-quarter 2012 preliminary IFRS total revenue to 3.35 billion euros from the prior year's 3.02 billion euros. On a non-IFRS basis, preliminary revenue for the quarter amounted to 3.36 billion euros, 10% higher than 3.04 billion euros a year earlier.

In addition, SAP issued its second-quarter guidance, expecting software revenue to increase in a range of 15% - 20% at constant currencies, and non-IFRS software and software-related service revenue growth in a range of 14% - 16% at constant currencies.

For the full year 2012, the company anticipates non-IFRS software and software-related service revenue to increase in a range of 10% - 12% at constant currencies, including a contribution of up to 2 percentage points from SuccessFactors' business. Full-year non-IFRS operating profit is projected to be in a range of euro 5.05 billion euros - 5.25 billion euros at constant currencies.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Snack and beverage giant Pepsico Inc. reported Thursday significantly higher profit in its third quarter, reflecting the absence of last year's hefty Venezuelan impairment charges, despite weak revenues. Core earnings and revenues beat market estimates. Further, the company lifted its fiscal 2016 forecast on its performance and outlook for the fourth quarter. Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects.
comments powered by Disqus
Follow RTT